Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report

References

• Coleman JJ, Pontefract SK. Adverse drug reactions. Clin med. 2016;16(5):481–485. doi:10.7861/clinmedicine.16-5-481
   PubMed Web of Science ®Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm j. 2014;22(2):83–94. doi:10.1016/j.jsps.2013.02.003
   PubMed Web of Science ®Google Scholar
• Malki MA, Pearson ER. Drug–drug–gene interactions and adverse drug reactions. Pharmacogenomics J. 2020;20(3):355–366. doi:10.1038/s41397-019-0122-0
   PubMed Web of Science ®Google Scholar
• Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int J Clin Pharm. 2023;1–10.
   Web of Science ®Google Scholar
• Sabaté Gallego M, Pérez Esquirol E, Garcia Doladé N, et al. Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice. Front med. 2022;9:891179. doi:10.3389/fmed.2022.891179
   Web of Science ®Google Scholar
• Khalil H, Huang C. Adverse drug reactions in primary care: a scoping review. BMC Health Serv Res. 2020;20(1):5. doi:10.1186/s12913-019-4651-7
   PubMed Web of Science ®Google Scholar
• Phillips EJ. Classifying ADRs--does dose matter? Br J Clin Pharmacol. 2016;81:10–12. doi:10.1111/bcp.12749
   PubMed Web of Science ®Google Scholar
• Jin S, Sun Y, Liang X, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction Targeted Therapy. 2022;7:39.
   PubMed Web of Science ®Google Scholar
• Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel, Switzerland). 2020;9(3). doi:10.3390/antib9030034
   PubMedGoogle Scholar
• Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: a promising anti-tumor PD-1 antibody. Front Oncol. 2020;10:594558. doi:10.3389/fonc.2020.594558
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin W, Tan F, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomarker Res. 2022;10(1):23. doi:10.1186/s40364-022-00363-7
   PubMed Web of Science ®Google Scholar
• Wang J, Fei K, Jing H et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 2019;11(8):1443–1451.
   PubMed Web of Science ®Google Scholar
• Salati M, Pifferi M, Baldessari C, et al. Stevens-Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol. 2018;29:283–284. doi:10.1093/annonc/mdx640
   PubMed Web of Science ®Google Scholar
• Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thoracic Oncol. 2020;15(5):816–826. doi:10.1016/j.jtho.2020.01.017
   PubMed Web of Science ®Google Scholar
• Zimmerman D, Dang NH. Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): immunologic Reactions. Oncologic Critical Care. 2019;267–280. doi:10.1007/978-3-319-74588-6_195
   Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Sheth H, Pragya R, Kovale S, et al. Oral mucositis—case series of a rare adverse effect associated with immunotherapy. Supportive Care Cancer. 2021;29(8):4705–4709. doi:10.1007/s00520-021-05993-5
   PubMed Web of Science ®Google Scholar
• Peña-Cardelles JF, Salgado-Peralvo AO, Garrido-Martínez P, Cebrián-Carretero JL, Pozo-Kreilinger JJ, Moro-Rodríguez JE. Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review. Med Oral Patol Oral Cir Bucal. 2021;26:e494–e501. doi:10.4317/medoral.24353
   PubMed Web of Science ®Google Scholar
• Fazer C, Price KA. Management of immune-related dermatitis and mucositis associated with pembrolizumab in metastatic human papillomavirus–associated squamous cell carcinoma of the oropharynx. J Oncol Practice. 2020;16:20s–24s. doi:10.1200/JOP.19.00648
   Google Scholar
• Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022;13:868695. doi:10.3389/fphar.2022.868695
   PubMed Web of Science ®Google Scholar
• Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294. doi:10.1097/CCO.0000000000000296
   PubMed Web of Science ®Google Scholar
• Ishida T, Ito A, Sato F, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma. Cancer Sci. 2013;104(5):647–650. doi:10.1111/cas.12116
   PubMed Web of Science ®Google Scholar
• Venkateswaran N, Khianey R, Generoso A. Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy. Cureus. 2020;12(4):e7662. doi:10.7759/cureus.7662
   PubMed Web of Science ®Google Scholar
• Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25(2):225–234. doi:10.1097/CAD.0000000000000032
   PubMed Web of Science ®Google Scholar
• Smelik M. Stevens-Johnson Syndrome: a Case Study. Perm J. 2002;6(1):29–31. doi:10.7812/TPP/02.997
   PubMedGoogle Scholar
• Tomasini P, Mascaux C, Jao K, et al. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated with Chemotherapy for Non–Small-Cell Lung Cancer. Clin Lung Cancer. 2019;20(3):e338–e345. doi:10.1016/j.cllc.2018.12.009
   PubMed Web of Science ®Google Scholar
• Pandey R, Johnson N, Cooke L, et al. TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients. Cancers. 2021;13(4):597. doi:10.3390/cancers13040597
   PubMed Web of Science ®Google Scholar
• Gu M, Xu T, Chang P. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol. 2021;13:17588359211006950. doi:10.1177/17588359211006950
   Web of Science ®Google Scholar
• Zeng L, Li Y, Xiao L, et al. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. Onco Targets Ther. 2018;11:6937–6945. doi:10.2147/OTT.S176273
   PubMed Web of Science ®Google Scholar
• Riviere P, Goodman AM, Okamura R, et al. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse CancersTMB and Overall Survival. Mol Cancer Ther. 2020;19(10):2139–2145. doi:10.1158/1535-7163.MCT-20-0161
   PubMed Web of Science ®Google Scholar
• Lin G, Fan X, Zhu W, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017;8(48):83986–83994. doi:10.18632/oncotarget.20233
   PubMedGoogle Scholar
• Bonaventura P, Shekarian T, Alcazer V, et al. Cold Tumors: a Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168. doi:10.3389/fimmu.2019.00168
   PubMed Web of Science ®Google Scholar
• Wang D-R, Wu X-L, Sun Y-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduction Targeted Therapy. 2022;7(1):331. doi:10.1038/s41392-022-01136-2
   PubMed Web of Science ®Google Scholar
• Das S, Ramamoorthy R. Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Indian J Paediatric Dermatol. 2018;19(1):9–14. doi:10.4103/ijpd.IJPD_120_17
   Google Scholar
• Hoy SM. Sintilimab: first global approval. Drugs. 2019;79(3):341–346. doi:10.1007/s40265-019-1066-z
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, Phase 2 trial. Lancet Haematol. 2019;6(1):e12–e19. doi:10.1016/S2352-3026(18)30192-3
   PubMed Web of Science ®Google Scholar
• Mawson AR, Eriator I, Karre S. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role? Med Sci Monitor. 2015;21:133–143. doi:10.12659/MSM.891043
   PubMed Web of Science ®Google Scholar
• Venkateshwarlu M, Radhika B. Diagnosis and management of drug-induced Stevens-Johnson syndrome: report of two cases. J Indian Acad Oral Med Radiol. 2011;23:S429–S433. doi:10.5005/jp-journals-10011-1189
   Google Scholar
• Auyeung J, Lee M. Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid. Can J Hosp Pharm. 2018;71(4):272–275. doi:10.4212/cjhp.v71i4.2829
   PubMed Web of Science ®Google Scholar
• Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis: an Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82:603. doi:10.4103/0378-6323.191134
   PubMed Web of Science ®Google Scholar
• Czajkowski R, Weiss-Rostkowska V, Wankiewicz A, et al. Stevens-Johnson syndrome induced by carbamazepine. Acta Pol Pharm. 2007;64:89–92.
   PubMedGoogle Scholar
• Wilken R, Li CS, Sharon VR, et al. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial. Trials. 2015;16(1):374. doi:10.1186/s13063-015-0879-7
   PubMedGoogle Scholar
• Hollingsworth J, Park SU, Bhagavathi V, Green A, Philips N. Stevens-Johnson syndrome with vulvar involvement: a case report and literature review. Case Rep Women’s Health. 2022;34:e00404. doi:10.1016/j.crwh.2022.e00404
   PubMedGoogle Scholar
• Li G, Gong S, Wang N, Yao X. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: a case report. Front Immunol. 2022;13:989966. doi:10.3389/fimmu.2022.989966
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen G, He Z, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine. 2021;37:100951. doi:10.1016/j.eclinm.2021.100951
   PubMedGoogle Scholar
• Zhao Y, Cao Y, Wang X, Qian T. Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: a Case Report and Brief Review. OncoTargets and Therapy. 2022;15:345–351. doi:10.2147/OTT.S353743
   PubMed Web of Science ®Google Scholar
• Lee O, Masood M, Nutan F. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/Ipilimumab Combination Therapy in Metastatic Melanoma. J Drugs Dermatol. 2022;21(5):529–530. doi:10.36849/JDD.6559
   PubMed Web of Science ®Google Scholar
• Kubicki SL, Welborn ME, Patel AB. Toxic epidermal necrolysis during cotherapy with ipilimumab and nivolumab. J Immunother Precision Oncol. 2018;1(2):78–81. doi:10.4103/JIPO.JIPO_7_18
   Google Scholar
• Borg L, Buhagiar M, La Ferla E, Pisani D, Said J, Boffa MJ. Pembrolizumab-Induced Toxic Epidermal Necrolysis. Case Rep Oncol. 2022;15(3):887–893. doi:10.1159/000526931
   PubMed Web of Science ®Google Scholar
• Neema S, Sathu S, Vasudevan B, Shreshta S, Bhatt S, Lekshmipriya K. Pembrolizumab-induced toxic epidermal necrolysis: a rare cause of severe adverse drug reaction. Indian J Dermatol Venereol Leprol. 2023;1–4. doi:10.25259/IJDVL_7_2023
   Web of Science ®Google Scholar
• Cao J, Li Q, Zhi X, et al. Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report. Transl Cancer Res. 2021;10(8):3870. doi:10.21037/tcr-21-470
   PubMed Web of Science ®Google Scholar